CorMedix Inc. Stock price

Equities

CRMD

US21900C3088

Pharmaceuticals

Delayed Nasdaq 04:00:00 2023-10-02 pm EDT Intraday chart for CorMedix Inc. 5-day change 1st Jan Change
3.540 USD -4.32% -4.07% -16.11%
Sales 2023 * 0 M Sales 2024 * 37 M Capitalization 203 M
Net income 2023 * -51 M Net income 2024 * -42 M EV / Sales 2023 *
-591x
Net cash position 2023 * 55 M Net cash position 2024 * 43 M EV / Sales 2024 *
4,34x
P/E ratio 2023 *
-3,62x
P/E ratio 2024 *
-5,19x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float99.11%
More Fundamentals * Assessed data
Dynamic Chart
1 day-4.32%
1 week-4.07%
Current month-4.32%
1 month-10.38%
3 months-9.23%
6 months-18.24%
Current year-16.11%
More quotes
1 week
3.52
Extreme 3.52
3.79
1 month
3.52
Extreme 3.52
4.18
Current year
3.20
Extreme 3.2
6.09
1 year
2.71
Extreme 2.71
6.09
3 years
2.65
Extreme 2.645
18.80
5 years
2.16
Extreme 2.16
18.80
10 years
0.86
Extreme 0.8605
52.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 47 2022
Director of Finance/CFO 46 2020
Chief Tech/Sci/R&D Officer 44 2018
Members of the board TitleAgeSince
Director/Board Member 47 2022
Chairman 78 2017
Director/Board Member 67 2017
More insiders
Date Price Change Volume
23-10-02 3.540 -4.32% 482,871
23-09-29 3.700 +0.27% 530,016
23-09-28 3.690 +0.54% 506,838
23-09-27 3.670 +0.27% 342,452
23-09-26 3.660 -0.81% 372,237

Delayed Quote Nasdaq, October 02, 2023 at 04:00 pm EDT

More quotes
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on developing its product DefenCath, which is an antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic emodialysis. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL intended for the reduction of catheter-related infections and thrombosis in patients requiring central venous catheters CVCs in clinical settings, such as hemodialysis, total parenteral nutrition and oncology. In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
Calendar
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.700USD
Average target price
13.75USD
Spread / Average Target
+271.62%
Consensus
  1. Markets
  2. Equities
  3. Stock CorMedix Inc. - Nasdaq
Discover our Free Content to Help You Better Understand the Stock Market.
100% Free Registration
fermer